Is this the same J&J that forged a reputation for consumer safety with the Tylenol recall. The following was reported in today’s NJ Law Journal:
JOHNSON & JOHNSON UNIT TO PAY $85M FINE FOR MISBRANDING HEART DRUGS
Johnson & Johnson subsidiary Scios Inc. pleaded guilty last Wednesday to a criminal misdemeanor count of misbranding its heart disease drug, Natrecor, and agreed to pay an $85 million fine. Under Scios’s deal with federal prosecutors, the company admitted that it had intended to market Natrecor for use in infusions for non-acute congestive heart failure patients. The Food and Drug Administration had approved Natrecor in 2001, but only for patients suffering from acute CHF. Under the terms of the plea agreement, the government agreed not to prosecute Scios for any other related claims under the Food, Drug, and Cosmetic Act concerning the marketing and sale of Natrecor.